AHA 2019: 11 Late Breaking Clinical Trials At-a-Glance

The results seen with the only oral GLP-1 receptor agonist reflect "a profound clinical impact" for adults at high risk for MACE who are averse to injectable therapy.

Listen to our latest podcast episode for details on top CVD risk factors to screen patients with obesity for, medications to help prevent CVD, and more.

Your daily dose of the clinical news you may have missed.

Patrick Moriarty, MD, from the University of Kansas Medical Center, discusses the role of Lp(a) as a risk factor for cardiovascular disease and the phase 3 trials of a potential treatment.

ACC 2025: Black women and women in Southern states faced significantly higher rates of maternal mortality, according to a new study.

For the same level of baseline health, the increase in risk related to each of 8 key CV risk factors appears significantly higher in women than in men.